Compare WLDN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | NNNN |
|---|---|---|
| Founded | 1964 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Military/Government/Technical | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2006 | N/A |
| Metric | WLDN | NNNN |
|---|---|---|
| Price | $91.81 | $33.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $114.50 | N/A |
| AVG Volume (30 Days) | ★ 450.6K | 14.9K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $273,352,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.05 | N/A |
| P/E Ratio | ★ $167.37 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.44 | $7.76 |
| 52 Week High | $137.00 | $55.65 |
| Indicator | WLDN | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 66.49 |
| Support Level | $86.37 | $26.31 |
| Resistance Level | $98.22 | $44.06 |
| Average True Range (ATR) | 4.99 | 3.05 |
| MACD | 0.26 | 0.66 |
| Stochastic Oscillator | 51.00 | 90.43 |
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).